Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 229 results
A molecular model in a dimly lit lab setting, emphasizing the intersection of AI and drug development.

Jun 12, 2026

Smart Money Bets Big on AI in Pharma

Investors are increasingly turning their attention to healthcare technology, particularly in the pharmaceutical sector, where machine learning is transforming drug development timelines from decades to just months. This shift is prompting a significant reallocation of capital towards biotech firms that leverage computational techniques, as traditional drug discovery methods become less viable.Machine learning technologies are enabling laboratories to predict molecular behaviors with remarkable a
Minimalist illustration of a drug compound

Jun 12, 2026

MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery

Dr. Jennifer Bath, CEO of MindWalk, will participate in a virtual panel on AI-driven drug discovery, alongside Absci and a leading AI compute provider, during Jones AI Day on June 15, 2026.The panel, titled “Partnering to Power the New Era of Drug Discovery,” will delve into how advancements in high-performance computing and generative AI can overcome traditional obstacles in drug development. This includes addressing long screening timelines and tackling historically challenging targets. Modera
A molecular model on a lab bench with simulation data papers in a dimly lit laboratory.

Jun 12, 2026

AI model accelerates molecular simulations by 10,000-fold

A new AI framework, TITO, has been introduced, promising to revolutionize molecular simulations by accelerating them by up to 10,000 times. This advancement, published in *Science Advances*, leverages deep generative modeling to learn the statistical rules of molecular motion from existing simulation data.Traditional molecular dynamics simulations operate on a timescale of approximately one femtosecond, which leads to extensive computational demands for processes relevant to drug development. TI
A vial of a drug compound on a laboratory surface with notes and a beaker in the background.

Jun 11, 2026

Sygnature Discovery partners with DaltonTx to enhance AI-driven drug discovery capabilities

Sygnature Discovery has announced a strategic partnership with DaltonTx to bolster its AI-driven drug discovery capabilities, focusing on enhancing decision-making in medicinal chemistry while ensuring secure data management.DaltonTx leverages its Dalton platform, which merges drug discovery expertise with advanced software engineering and artificial intelligence. This platform integrates various data sources, computational models, and experimental outcomes into a cohesive learning system that s
A test tube filled with colorful liquid in a laboratory setting.

Jun 10, 2026

Build AI-Ready Pharma R&D to Accelerate Drug Development, Upcoming Webinar Hosted by Xtalks

A webinar hosted by Xtalks will delve into how AI and unified data platforms can enhance drug development in the pharmaceutical sector. The session aims to provide actionable insights for building an AI-ready infrastructure that fosters innovation while ensuring compliance.As the pharmaceutical industry faces increasing pressure to innovate rapidly and manage complex data landscapes, this webinar will highlight strategies used by leading organizations to integrate AI into their research and deve
A minimalist representation of DNA and data integration

Jun 10, 2026

MindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery

MindWalk Holdings Corp. has introduced ReefIQ™, a new biological context layer designed to enhance AI-driven drug discovery and biologics development.This innovative platform aims to bridge the gap in fragmented drug-discovery data, which often exists in disparate formats and systems. By integrating various biological representations—such as sequences, structures, and assay outputs—ReefIQ provides a cohesive, governed context that can be utilized by AI workflows. This integration is critical as
Flat design of a small-molecule drug and GPCR icon

Jun 10, 2026

XTALPI (02228.HK) Enters Strategic AI Drug Discovery Collaboration with International Pharma Worth Over USD400 Million

XTALPI has formed a significant strategic partnership with an international biopharmaceutical firm to co-develop an innovative oral small-molecule drug aimed at targeting G protein-coupled receptors (GPCRs).This collaboration follows a successful pilot phase where XTALPI utilized its advanced platform, integrating quantum physics and AI algorithms, to enhance its drug discovery hit rate. Under the terms of the agreement, the biopharmaceutical partner will provide an upfront payment and cover all
A vaccine vial and syringe in a dimly lit lab setting, symbolizing AI vaccine development.

Jun 9, 2026

AI Vaccine Clears Human Trials, Handing Pharma a New Playbook

A groundbreaking AI-designed vaccine has successfully passed its initial human safety trial, signaling a potential shift in pharmaceutical development.The vaccine, created by the University of Cambridge and its spinout DIOSynVax, demonstrates a novel approach by utilizing AI to analyze global virus surveillance data rather than starting with a known pathogen. This method allowed the AI to identify patterns across various virus variants and develop a vaccine component that human researchers had n
minimalist representation of a small molecule

Jun 9, 2026

Evogene to Present Its Pharma Division Achievements at the BIO International Convention

Evogene Ltd. is set to showcase its advancements in drug discovery at the upcoming BIO International Convention, scheduled for June 22-25, 2026, in San Diego, California.The company, known for its innovative work in computational chemistry and AI-driven design of small molecules, will highlight its recent breakthroughs in pharmaceutical applications. Ofer Haviv, the CEO, along with Dr. Gabi Tarcic and Dr. Olga Nissan, will represent Evogene at the event. Dr. Tarcic is expected to present on the
Flat design of a drug compound and AI agent silhouette

Jun 8, 2026

Owkin, Sanofi Expand AI Collaboration to Develop Drug Discovery Agents

Owkin and Sanofi have deepened their partnership to enhance drug discovery through AI technology, marking a significant step in integrating advanced digital tools into pharmaceutical research.The newly expanded five-year collaboration will leverage Owkin's K Pro AI scientist platform to develop AI-driven agents tailored for Sanofi's drug development processes. This initiative aims to create intelligent assistants capable of executing complex tasks throughout various phases of research and develo
Flat illustration of siRNA molecule and AI model

Jun 6, 2026

How a US$2 Billion Generative AI RNAi Deal At Alnylam Pharmaceuticals (ALNY) Has Changed Its Investment Story

Alnylam Pharmaceuticals has entered a significant partnership with Inceptive Nucleics, valued at up to $2 billion, aimed at leveraging generative AI to enhance RNAi drug discovery. This collaboration includes an initial investment of $30 million and grants Alnylam access to advanced AI models and expertise, notably from Transformer co-inventor Jakob Uszkoreit, to improve siRNA design and overall research productivity.This partnership is poised to reshape Alnylam's investment narrative as it seek
A minimalist representation of a molecule and a computer chip, symbolizing AI in drug discovery.

Jun 6, 2026

NYB.AI Featured in NVIDIA GTC Taiwan

NYB.AI, an AI-driven drug discovery platform, has gained recognition at NVIDIA GTC Taiwan 2026, showcasing its innovative potential in the life sciences sector.Developed by Nanyang Biologics, NYB.AI was highlighted in the opening showcase video at the event, which featured select companies from the NVIDIA Inception ecosystem. This recognition underscores the growing global interest in integrating artificial intelligence with biology and high-performance computing to enhance drug discovery proces